Researchers have known for years that antiphospholipid antibodies (aPLs) can trigger the production of proteins that can cause inflammation and increase the risk of formation of clots.
Now a new study provides the first estimates of the prevalence of these antibodies in patients suffering from pregnancy loss, stroke, myocardial infarction, and deep vein thrombosis.
While some aPL-positive individuals develop blood clots, strokes, and pregnancy complications, others are perfectly healthy. Individuals who are aPL-positive and have either venous thrombosis, arterial thrombosis, or fetal loss are classified as having antiphospholipid syndrome (APS).
The study will be presented during the annual meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP).